Abbott Laboratories vs Packaging Corporation of America — how do they compare? Abbott Laboratories trades at $109.85 (market cap $187.95B), while Packaging Corporation of America trades at $257.2 (market cap $22.70B). The key difference: Abbott Laboratories is far larger — about 8.3× Packaging Corporation of America's market cap, and Packaging Corporation of America pays the higher dividend (2.36%). Which is the better fit depends on your goals.
| ABT | PKG | |
|---|---|---|
Market Cap | $187.95B | $22.70B |
Sector | Health | Technology |
52-Week High | $136.62 | $256.04 |
52-Week Low | $82.57 | $191.68 |
Enterprise Value | $214.96B | $26.51B |
Dividend Yield | 2.32% | 2.36% |
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $107.80, down slightly by 0.14% today. The stock shows a bullish technical signal with strong moving average support and a consensus analyst price target of $120.70. Recent earnings beat expectations in Q1 and Q2 2026, while revenue grew to $44.33 billion in 2025. The company secured a CE Mark for its Libre Duo glucose-ketone sensor, highlighting innovation in diabetes care.
The outlook remains positive given analyst consensus and recent product approvals, but risks include competitive pressures and macroeconomic volatility. Upside potential exists if earnings momentum continues, though valuation multiples are above industry averages, warranting caution on significant expansion.
Packaging Corporation of America (PKG) trades at $256.04, up 1.3% on the day, with a bullish technical trend supported by moving averages and strong support at $252. The company reported Q2 2026 EPS of $2.35, beating estimates, driven by record corrugated shipments and contributions from the Greif acquisition, though net income margins face pressure from rising costs. A $1.50 dividend for H1-2026 reflects management's confidence, with a consensus price target of $269.33 suggesting modest upside.
Outlook: PKG benefits from robust demand and strategic acquisitions, but cost headwinds and a high P/E of 33.08 pose valuation risks. Analyst sentiment is mixed with 34.6% buy ratings, indicating cautious optimism amid margin compression and economic uncertainties. Key risks include freight and input cost inflation, competitive pricing pressure, and execution of integration synergies.
Trailing returns across standard periods
Latest headlines on both assets
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →Packaging Corporation of America is a leading producer of containerboard and corrugated packaging products in North America. The company also produces white papers, which include printing and writing papers. PKG operates as an integrated manufacturer, with a strong focus on high-quality and sustainable packaging solutions for e-commerce, food and beverage, and other industrial and consumer markets.
Read more on PKG →